

HOLD

TP: Rs 2,712 | ▲ 6%

HERO MOTOCORP

| Automobiles

| 05 May 2023

Improved performance; sustainability to be seen

- Q4 revenue grew 12% YoY backed by 5% higher net realisation per vehicle and volume gains of 7%
- Gross margin improved 132bps YoY to 32% largely due to easing of raw material price, price pass thru only
- We value HMCL at 13x (15x) as we rollover valuations over to FY25 with at TP of Rs 2,712 (unchanged) Maintain HOLD.

Milind Raginwar | Yash Thakur
research@bobcaps.in

Healthy volumes and realisations: HMCL's Q4FY23 revenue grew 12% YoY (+3% QoQ) to Rs 83bn as volumes increased by 7% (+2.5% QoQ) to 1.3mn units. Despite the volume push, net realisation per vehicle (NRPV) grew 5% YoY (+1% QoQ) to Rs 65.4k.

Operating leverage aids margin improvement: Raw material cost (adjusted to inventory jumped) 10%/1% YoY/QoQ and as % of sales was at 68% vs 69.3% in Q4FY22, aiding gross margin improvement of 132bps YoY (+144bps QoQ) to 32% Operating leverage on other expenses (70-80bps) and leap cost savings initiatives further aided EBITDA margin gains. EBITDA increased 31% YoY (+17% QoQ) to Rs 10.8bn with margin expansion of 189bps YoY (+153bps QoQ) to 13%. Other expenditure grew by 5%/3% YoY/QoQ at Rs 10.2bn. Adj. PAT climbed 37% YoY (+21% QoQ) to Rs 8.6bn further backed by a 70% surge in other income to Rs 2.4bn (+29% QoQ).

Focus on launches: Management indicated aggressive new launches across segments in every quarter of FY24. Further, the focus will be on recovery in the 125cc segment, building the premium portfolio and improving market share.

Rural demand picking up: Rural demand witnessed an uptick in the month of March on account of festivals, and management expects the growth momentum to continue in the wake of the wedding season and anticipates well-balanced growth across segments. Retail finance penetration has risen to 59%, which is further aiding volume growth.

Retain HOLD: We model for a revenue/EBITDA/adj. 15%/19%/17% for HMCL over FY22-FY25, with EBITDA margin averaging at ~13%. Our FY24/FY25 EPS remains at Rs 174/Rs 200. we await rural recovery, export market revival and the response to HMCL's aggressive launch programme before upgrading our estimates. We reset our target P/E multiple from 15 to 13x as we rollover valuations over to FY25 (earlier FY24), our SOTP-based TP remains unchanged at Rs 2,712, offering 6% upside. Maintain HOLD.

Key changes

Target	Rating
◀ ▶	◀ ▶

Ticker/Price	HMCL IN/Rs 2,547
Market cap	US\$ 6.2bn
Free float	65%
3M ADV	US\$ 14.1mn
52wk high/low	Rs 2,939/Rs 2,246
Promoter/FPI/DII	35%/30%/24%


Source: NSE | Price as of 5 May 2023

Key financials

Y/E 31 Mar	FY23P	FY24E	FY25E
Total revenue (Rs mn)	3,38,057	3,82,719	4,39,853
EBITDA (Rs mn)	39,862	48,969	56,675
Adj. net profit (Rs mn)	29,105	34,773	40,101
Adj. EPS (Rs)	145.8	174.1	200.8
Consensus EPS (Rs)	145.8	173.8	194.5
Adj. ROAE (%)	17.4	18.9	19.7
Adj. P/E (x)	17.5	14.6	12.7
EV/EBITDA (x)	12.7	10.3	8.8
Adj. EPS growth (%)	17.7	19.5	15.3

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE



Fig 1 – Earnings call highlights

Parameter	Q4FY23	Q3FY23	Our view
Market share	<p>HMCL's 2W market share grew 3% QoQ and 2% YoY; motorcycle share was 51%.</p> <p>Market share in the 125cc segment increased to 22% from 14% with a target of 50% over the next two years.</p> <p>HMCL has 7-8% market share in the ICE scooter portfolio.</p>	<p>Management aims to regain 125cc market share, for which multiple launches are lined up, not only for the coming year but for the next 3-5 years.</p> <p>HMCL's scooter market share grew from 6% to 9%.</p>	Retention of leadership in the lower end 100cc bikes is key. HMCL has an aggressive plan to build presence in higher end bikes but faces stiff competition.
Margins	<p>EBITDA margin recovered by close to 200bps YoY, of which 70-80bps was on account of operating leverage and the rest came from Project Leap savings, commodity softening and price hikes. Management does not expect any escalation in commodity prices.</p> <p>Pricing increased by ~Rs 4,000 per vehicle for FY23 and a further Rs 600 in April.</p> <p>Management gave out longer term margin guidance of 14-16%.</p>	<p>Margins improved on the back of price hikes (Aug: Rs 300, Sep: Rs 500, Dec: Rs 930), Project Leap savings (80bps over 9M) and commodity softening (150-200bps YoY).</p> <p>Management indicated that price hikes related to OBD2 norms are not material and are expected to be in the range of Rs 500 to Rs 800 per vehicle.</p>	Margin recovery though welcome is limited only to passthrough of higher costs. The trigger will be margin accretion and reaching the previous high trajectory.
Premiumisation	HMCL's premium motorcycle segment (150cc+) has grown 28% in FY23 vs. category growth of 14%.	Management aims to build meaningful premium segment market share in the medium term.	HMCL lags behind in the premium segment, though its current strategy of targeting high-end products is a step in the right direction.
Electric vehicles	Prices of <i>Vida</i> were revised down to boost demand; this model is currently available in 8 cities and will be taken to 100 cities in FY24. At present, management sees no capacity constraints for EV ramp-up.	During the quarter, HMCL commenced deliveries of <i>Vida</i> and is now present in three cities.	EV plans are aggressive and face competition.
Exports	HMCL derived 5% of volumes from exports (vs. 25% for the industry) and expects to scale this up to 10-15% of revenue in the medium term.	Global business is targeted to contribute at least 10% of overall revenue over the medium to long term.	Export turnaround will have to wait given global weakness; however, this is an industrywide issue.
Others	<p>Management expects double-digit revenue growth for the 2W industry in FY24.</p> <p>Spares revenue stood at Rs 12.7 against Rs 11.5bn in Q4FY22.</p> <p>Export revenue for FY23 was Rs 11.5bn.</p>	Spares revenue was at Rs 12.6bn vs. Rs 11.9bn in Q3FY22.	Other revenue streams are steady.

Source: Company, BOBCAPS Research | 2W: Two-wheelers, ICE: Internal Combustion Engine, OBD: Onboard Diagnostics

Fig 2 – Quarterly performance

(Rs mn)	Q4FY23	Q4FY22	YoY (%)	Q3FY23	QoQ (%)	FY23	FY22	YoY (%)
Volume	1,270,492	1,188,884	6.9	1,239,693	2.5	5,328,546	4,944,132	7.8
Avg. Realisation per Vehicle	65,382	62,426	4.7	64,782	0.9	63,443	59,152	7.3
Net Revenues	83,068	74,217	11.9	80,310	3.4	338,057	292,455	15.6
Total Income (A)	83,068	74,217	11.9	80,310	3.4	338,057	292,455	15.6
Operating Expenses:								
Raw materials consumed	56,463	51,424	9.8	55,743	1.3	238,581	208,267	14.6
Employee Expenses	5,571	4,763	16.9	5,456	2.1	21,898	19,354	13.1
Other Expenses	10,204	9,754	4.6	9,869	3.4	37,715	31,145	21.1
Total Expenditure (B)	72,238	65,942	9.5	71,068	1.6	298,194	258,767	15.2
EBITDA (A-B)	10,830	8,276	30.9	9,241	17.2	39,862	33,688	18.3
Other Income	2,369	1,398	69.5	1,832	29.3	5,652	5,569	1.5
Depreciation	1,686	1,585	6.4	1,620	4.1	6,570	6,498	1.1
EBIT	11,513	8,089	42.3	9,453	21.8	38,944	32,759	18.9
Finance Costs	47	67	(29.7)	49	(4.5)	199	258	(23.0)
PBT before exceptional items	11,467	8,022	42.9	9,404	21.9	38,746	32,501	19.2
Exceptional items	-	-	-	-	-	-	-	-
PBT after exceptional items	11,467	8,022	42.9	9,404	21.9	38,746	32,501	19.2
Tax expense	2,877	1,752	64.3	2,294	25.4	9,640	7,771	24.0
Reported PAT	8,589	6,271	37.0	7,111	20.8	29,106	24,730	17.7
Adjusted PAT	8,589	6,271	37.0	7,111	20.8	29,106	24,730	17.7
Adj EPS (Rs)	43.0	31.4	37.0	35.6	20.8	146	123.9	17.7
Key Ratios (%)			(bps)		(bps)			(bps)
Gross Margin	32.0	30.7	132	30.6%	144	29.4	28.8	64
EBITDA Margin	13.0	11.2	189	11.5%	153	11.8	11.5	27
EBIT Margin	13.9	10.9	296	11.8%	209	11.5	11.2	32
PBT Margin	13.8	10.8	299	11.7%	209	11.5	11.1	35
Tax Rate	25.1	21.8	326	24.4%	70	24.9	23.9	97
Adj PAT Margin	10.3	8.4	189	8.9%	149	8.6	8.5	15

Source: Company, BOBCAPS Research

Valuation methodology

We model for a revenue/EBITDA/adj. PAT CAGR of 15%/19%/17% for HMCL over FY22-FY25, with EBITDA margin averaging at ~13%. Our FY24/FY25 EPS remains at Rs 174/Rs 200. We await rural recovery, export market revival and the response to HMCL's aggressive launch programme before upgrading our estimates. We reset our target P/E multiple from 15 to 13x as we rollover valuations over to FY25 (earlier FY24), our SOTP-based TP remains unchanged at Rs 2,712, offering 6% upside. Maintain HOLD.

Fig 3 – Key assumptions

Parameter	FY22	FY23	FY24E	FY25E
Volume	4,944,132	5,328,546	5,813,208	6,332,743
Realisation (Rs)	59,152	63,443	65,836	69,457
EBITDA (Rs)	33,688	39,862	48,969	56,675
EBITDA margin (%)	11.5	11.8	12.8	12.9
Adj. PAT (Rs)	24,730	29,106	34,778	40,102
EPS (Rs)	124	146	174	201

Source: Company, BOBCAPS Research

Fig 4 – Valuation summary

Business	FY25E EPS (Rs)	Target P/E (x)	Value (Rs)
Standalone Business	201	13	2,612
Other Business	-	-	100
Total	-	-	2,712

Source: BOBCAPS Research

Fig 5 – Peer comparison

Company	Ticker	Rating	Target Price (Rs)	EPS (Rs)		ROE (%)	
				FY24E	FY25E	FY24E	FY25E
Hero Motocorp	HMCL IN	HOLD	2,712	174.1	200.8	19.8	20.7
TVS Motor Company	TVSL IN	HOLD	1,252	41.4	48.8	29.9	28.5
Bajaj Auto	BJAUT IN	HOLD	4,188	212.0	243.0	20.9	21.8

Source: BOBCAPS Research

Key risks

- A better-than-expected response to HMCL's high-end products in the 125cc+ segment would be a key upside risk to our estimates.
- Continued raw material cost inflation and later-than-expected demand revival, especially in the rural segment, represent key downside risks.

Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Ashok Leyland	AL IN	5.2	145	169	BUY
Bajaj Auto	BJAUT IN	15.8	4,463	4,188	HOLD
Eicher Motors	EIM IN	11.2	3,355	3,543	HOLD
Escorts	ESCORTS IN	3.4	2,067	1,742	SELL
Hero MotoCorp	HMCL IN	6.2	2,547	2,712	HOLD
Mahindra & Mahindra	MM IN	18.5	1,211	1,496	BUY
Maruti Suzuki	MSIL IN	33.1	8,949	9,858	HOLD
TVS Motor	TVSL IN	7.1	1,215	1,252	HOLD
VST Tillers Tractors	VSTT IN	0.3	2,426	2,802	BUY

Source: BOBCAPS Research, NSE | Price as of 5 May 2023

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Total revenue	3,08,006	2,92,455	3,38,057	3,82,719	4,39,853
EBITDA	40,193	33,688	39,862	48,969	56,675
Depreciation	6,769	6,498	6,570	7,469	8,383
EBIT	39,222	32,759	38,944	45,993	53,373
Net interest inc./(exp.)	(218)	(258)	(199)	(240)	(259)
Other inc./(exp.)	5,799	5,569	5,652	4,493	5,081
Exceptional items	0	0	0	0	0
EBT	39,004	32,501	38,745	45,753	53,114
Income taxes	9,362	7,771	9,640	10,981	13,013
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	29,642	24,730	29,105	34,773	40,101
Adjustments	0	0	0	0	0
Adjusted net profit	29,642	24,730	29,105	34,773	40,101

Balance Sheet

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Accounts payables	52,046	44,498	47,278	50,656	56,845
Other current liabilities	8,913	7,595	7,975	8,374	8,792
Provisions	3,328	3,385	3,738	3,925	4,121
Debt funds	0	0	0	0	0
Other liabilities	1,298	0	0	0	0
Equity capital	400	400	400	400	400
Reserves & surplus	1,51,585	1,57,429	1,66,651	1,83,367	2,03,499
Shareholders' fund	1,51,984	1,57,829	1,67,051	1,83,766	2,03,898
Total liab. and equities	2,17,570	2,13,307	2,26,041	2,46,721	2,73,657
Cash and cash eq.	2,572	1,751	3,455	8,856	9,370
Accounts receivables	24,268	23,043	27,982	26,790	29,910
Inventories	14,696	11,227	14,341	13,778	15,395
Other current assets	6,601	11,950	12,983	13,632	14,314
Investments	1,04,997	1,06,523	1,10,104	1,23,104	1,41,104
Net fixed assets	59,884	58,065	59,385	61,417	61,034
CWIP	4,366	4,582	1,845	3,400	7,000
Intangible assets	0	0	0	0	0
Deferred tax assets, net	(4,041)	(3,833)	(4,054)	(4,256)	(4,469)
Other assets	4,229	0	0	0	0
Total assets	2,17,570	2,13,307	2,26,041	2,46,721	2,73,657

Cash Flows

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Cash flow from operations	42,251	18,812	24,250	42,578	44,530
Capital expenditures	(6,435)	(4,894)	(5,153)	(11,055)	(11,600)
Change in investments	(22,770)	(1,526)	(3,580)	(13,000)	(18,000)
Other investing cash flows	5,799	5,569	5,652	4,493	5,081
Cash flow from investing	(23,407)	(852)	(3,082)	(19,562)	(24,519)
Equities issued/Others	131	106	0	0	0
Debt raised/repaid	0	0	0	0	0
Interest expenses	(218)	(258)	(199)	(240)	(259)
Dividends paid	(18,978)	(18,992)	(18,970)	(18,970)	(19,969)
Other financing cash flows	113	(208)	221	203	213
Cash flow from financing	(18,953)	(19,352)	(18,948)	(19,008)	(20,015)
Chg in cash & cash eq.	(109)	(1,391)	2,220	4,008	(4)
Closing cash & cash eq.	2,572	1,751	3,455	8,856	9,370

Per Share

Y/E 31 Mar (Rs)	FY21A	FY22A	FY23P	FY24E	FY25E
Reported EPS	148.4	123.8	145.8	174.1	200.8
Adjusted EPS	148.4	123.8	145.8	174.1	200.8
Dividend per share	95.0	95.1	95.0	95.0	100.0
Book value per share	761.1	790.4	836.6	920.3	1,021.1

Valuations Ratios

Y/E 31 Mar (x)	FY21A	FY22A	FY23P	FY24E	FY25E
EV/Sales	1.6	1.7	1.5	1.3	1.1
EV/EBITDA	12.6	15.0	12.7	10.3	8.8
Adjusted P/E	17.2	20.6	17.5	14.6	12.7
P/BV	3.3	3.2	3.0	2.8	2.5

DuPont Analysis

Y/E 31 Mar (%)	FY21A	FY22A	FY23P	FY24E	FY25E
Tax burden (Net profit/PBT)	76.0	76.1	75.1	76.0	75.5
Interest burden (PBT/EBIT)	99.4	99.2	99.5	99.5	99.5
EBIT margin (EBIT/Revenue)	12.7	11.2	11.5	12.0	12.1
Asset turnover (Rev./Avg TA)	208.2	188.0	208.1	218.2	226.9
Leverage (Avg TA/Avg Equity)	1.0	1.0	1.0	1.0	1.0
Adjusted ROAE	20.2	16.0	17.9	19.8	20.7

Ratio Analysis

Y/E 31 Mar	FY21A	FY22A	FY23P	FY24E	FY25E
YoY growth (%)					
Revenue	6.8	(5.0)	15.6	13.2	14.9
EBITDA	1.5	(16.2)	18.3	22.8	15.7
Adjusted EPS	0.3	(16.6)	17.7	19.5	15.3
Profitability & Return ratios (%)					
EBITDA margin	13.0	11.5	11.8	12.8	12.9
EBIT margin	12.7	11.2	11.5	12.0	12.1
Adjusted profit margin	9.6	8.5	8.6	9.1	9.1
Adjusted ROAE	19.5	15.7	17.4	18.9	19.7
ROCE	20.2	16.0	18.0	19.9	20.8
Working capital days (days)					
Receivables	24	30	28	26	24
Inventory	15	16	14	13	12
Payables	69	85	70	66	63
Ratios (x)					
Gross asset turnover	0.5	0.5	0.5	0.4	0.4
Current ratio	0.7	0.9	1.0	1.0	1.0
Net interest coverage ratio	(179.6)	(127.0)	(196.0)	(191.6)	(206.1)
Adjusted debt/equity	0.0	0.0	0.0	0.0	0.0

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): HERO MOTOCORP (HMCL IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom (“UK”):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.